FY2019 EPS Estimates for SAGE Therapeutics Inc Cut by Analyst (NASDAQ:SAGE)

SAGE Therapeutics Inc (NASDAQ:SAGE) – SunTrust Banks cut their FY2019 earnings per share (EPS) estimates for SAGE Therapeutics in a report issued on Wednesday, November 13th. SunTrust Banks analyst J. Lee now forecasts that the biopharmaceutical company will post earnings of ($13.44) per share for the year, down from their prior estimate of ($13.09). SunTrust Banks also issued estimates for SAGE Therapeutics’ Q4 2019 earnings at ($3.40) EPS, FY2020 earnings at ($12.36) EPS, FY2021 earnings at ($8.72) EPS and FY2022 earnings at ($0.95) EPS.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.41) by ($0.07). The company had revenue of $3.57 million during the quarter, compared to the consensus estimate of $2.52 million. SAGE Therapeutics had a negative net margin of 12,931.34% and a negative return on equity of 60.00%. The firm’s revenue was up 35600.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.63) earnings per share.

Several other research firms have also recently weighed in on SAGE. HC Wainwright started coverage on shares of SAGE Therapeutics in a report on Wednesday, October 30th. They issued a “neutral” rating and a $160.00 price target on the stock. Oppenheimer lowered their price target on shares of SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Canaccord Genuity lowered their price target on shares of SAGE Therapeutics from $220.00 to $218.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. BidaskClub cut shares of SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, November 1st. Finally, William Blair reissued a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $201.00.

SAGE Therapeutics stock opened at $146.32 on Monday. The stock has a market cap of $7.30 billion, a P/E ratio of -18.11 and a beta of 2.49. The company has a quick ratio of 16.00, a current ratio of 12.67 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a twelve month low of $79.88 and a twelve month high of $193.56. The company’s 50-day moving average price is $141.78 and its two-hundred day moving average price is $163.50.

Several institutional investors and hedge funds have recently made changes to their positions in the company. TimesSquare Capital Management LLC increased its holdings in shares of SAGE Therapeutics by 12.1% during the third quarter. TimesSquare Capital Management LLC now owns 570,500 shares of the biopharmaceutical company’s stock worth $80,035,000 after purchasing an additional 61,500 shares during the period. EFG Asset Management Americas Corp. increased its holdings in shares of SAGE Therapeutics by 6.1% during the third quarter. EFG Asset Management Americas Corp. now owns 21,679 shares of the biopharmaceutical company’s stock worth $3,041,000 after purchasing an additional 1,246 shares during the period. SG Americas Securities LLC increased its holdings in shares of SAGE Therapeutics by 77.0% during the third quarter. SG Americas Securities LLC now owns 3,737 shares of the biopharmaceutical company’s stock worth $524,000 after purchasing an additional 1,626 shares during the period. Picton Mahoney Asset Management increased its holdings in shares of SAGE Therapeutics by 14.0% during the third quarter. Picton Mahoney Asset Management now owns 19,356 shares of the biopharmaceutical company’s stock worth $2,716,000 after purchasing an additional 2,370 shares during the period. Finally, Comerica Bank increased its holdings in shares of SAGE Therapeutics by 302.1% during the third quarter. Comerica Bank now owns 7,580 shares of the biopharmaceutical company’s stock worth $1,075,000 after purchasing an additional 5,695 shares during the period.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Article: What is a Fibonacci Channel?

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.